✦ LIBER ✦

Response to O-TRP-6-LHRH (decapeptyl) in dvarian cancer

✍ Scribed by H. Parmar; R.H. Phillips; G. Rustin; D. Lucas; A.V. Schally; S.L. Lightman

Book ID: 116006622
Publisher: Elsevier Science
Year: 1987
Tongue: English
Weight: 114 KB
Volume: 28
Category: Article
ISSN: 0022-4731
DOI: 10.1016/0022-4731(87)91291-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

D-TRP-6-LHRH (decapeptyl) in advanced ov

D-TRP-6-LHRH (decapeptyl) in advanced ovarian cancer

✍ Parmar, H; Jager, W; Bottomley, D; Phillips, RH; Lightman, SL 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Long-acting (depot) D-TRP-6-LHRH(decapep

Long-acting (depot) D-TRP-6-LHRH(decapeptyl) in human prostate cancer. An Italian multicentric trial

✍ Boccardo, F.; Decansi, A.U.; Guerneri, D.; Martorane, G.; Giberti, C.; Cerruti, 📂 Article 📅 1987 🏛 Elsevier Science ⚖ 130 KB

Response to D-Trp-6-luteinising hormone

Response to D-Trp-6-luteinising hormone releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer

✍ H Parmar; G Rustin; SL Lightman 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 131 KB

O6-methylguanine-DNA methyltransferase (

O6-methylguanine-DNA methyltransferase (MGMT): impact on cancer risk in response to tobacco smoke

✍ Markus Christmann; Bernd Kaina 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 597 KB

Activity of O6-methylguanine-DNA methylt

Activity of O6-methylguanine-DNA methyltransferase in relation to p53 status and therapeutic response in ovarian cancer

✍ Jan G. Hengstler; Berno Tanner; Lars Möller; Rolf Meinert; Bernd Kaina 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 216 KB 👁 2 views

The DNA-repair protein O 6 -methylguanine-DNA methyltransferase (alkyltransferase; MGMT) is a major determinant of resistance of cells to various alkylating cytostatic drugs. Its expression in tissues is highly variable, indicating complex regulatory mechanisms involved. Transfection-mediated expres

Optimal Timing for Assessment of Tumor R

Optimal Timing for Assessment of Tumor Response to Neoadjuvant Chemoradiation in Patients With Rectal Cancer: Do All Patients Benefit From Waiting Longer Than 6 Weeks?

✍ Rodrigo O. Perez; Angelita Habr-Gama; Guilherme P. São Julião; Joaquim Gama-Rodr 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 449 KB